Shams K, Montgomery J, Morley J, Gerasimaviciute V, Seesaghur A, Neasham D
Dermatol Ther (Heidelb). 2025; .
PMID: 40080321
DOI: 10.1007/s13555-025-01358-6.
Guo H, Gao J, Gong L, Wang Y
J Transl Med. 2025; 23(1):100.
PMID: 39844246
PMC: 11752815.
DOI: 10.1186/s12967-025-06099-w.
Warren R, Pavlovsky L, Costanzo A, Bukhalo M, Korman N, Huang Y
Dermatol Ther (Heidelb). 2024; 14(12):3273-3290.
PMID: 39516454
PMC: 11604970.
DOI: 10.1007/s13555-024-01292-z.
De Sarro C, Bosco F, Gagliardi A, Guarnieri L, Ruga S, Fabiano A
Pharmaceutics. 2024; 16(10).
PMID: 39458658
PMC: 11510662.
DOI: 10.3390/pharmaceutics16101329.
Barlow R, Bewley A, Gkini M
JMIR Dermatol. 2024; 7:e50451.
PMID: 39413371
PMC: 11525079.
DOI: 10.2196/50451.
Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective.
Azizam N, Hussain M, Nauenberg E, Ang W, Azzeri A, Smith J
PLoS One. 2024; 19(9):e0307234.
PMID: 39240834
PMC: 11379230.
DOI: 10.1371/journal.pone.0307234.
The triglyceride-glucose index is a predictor of major adverse cardiovascular events in patients with coronary artery disease and psoriasis: a retrospective cohort study.
Fu B, Zeng Y, Wang M, Zhao L, Sun L, Wang T
Diabetol Metab Syndr. 2024; 16(1):184.
PMID: 39085887
PMC: 11290256.
DOI: 10.1186/s13098-024-01423-8.
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
Korge B, Vanhooteghem O, Lynde C, Machovcova A, Perrussel M, Lazaridou E
Dermatol Ther (Heidelb). 2024; 14(8):2077-2092.
PMID: 38937404
PMC: 11333646.
DOI: 10.1007/s13555-024-01210-3.
Management of Psoriasis Patients with Serious Infectious Diseases.
Megna M, Lauletta G, Tommasino N, Salsano A, Battista T, Ruggiero A
Adv Ther. 2024; 41(6):2099-2111.
PMID: 38709397
PMC: 11133026.
DOI: 10.1007/s12325-024-02873-2.
Targeted therapy for immune mediated skin diseases. What should a dermatologist know?.
Lopez E, Cabrera R, Lecaros C
An Bras Dermatol. 2024; 99(4):546-567.
PMID: 38521706
PMC: 11221168.
DOI: 10.1016/j.abd.2023.10.002.
Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive Treatment.
He C, Wu C, Zhang L, Jin H
Dermatol Ther (Heidelb). 2024; 14(4):893-906.
PMID: 38483777
PMC: 11052946.
DOI: 10.1007/s13555-024-01130-2.
Existing and Emerging Targeted Therapies in Juvenile Psoriatic Arthritis: Challenges and Unmet Needs.
Lokhandwala S, Townsend J, Ciurtin C
Paediatr Drugs. 2024; 26(3):217-228.
PMID: 38310623
DOI: 10.1007/s40272-023-00618-2.
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.
Torres T, Chiricozzi A, Puig L, Le A, Marzano A, Dapavo P
Am J Clin Dermatol. 2024; 25(2):333-342.
PMID: 38265746
PMC: 10867072.
DOI: 10.1007/s40257-024-00845-4.
Response of Psoriasis with Systemic Lupus Erythematosus to Secukinumab: A Case Report and Review of the Literature.
Dai B, Bai Y, Yu H, Huang Q, Wang L
Clin Cosmet Investig Dermatol. 2023; 16:3589-3594.
PMID: 38116143
PMC: 10729829.
DOI: 10.2147/CCID.S440977.
Non-pharmacological interventions for patients with psoriasis: a scoping review.
Zhang X, Lin J, Feng L, Ou M, Gong F
BMJ Open. 2023; 13(11):e074752.
PMID: 38000814
PMC: 10679995.
DOI: 10.1136/bmjopen-2023-074752.
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review.
Girolomoni G, Savage L, Gisondi P, Svensson A, Mahe E, Augustin M
Dermatol Ther (Heidelb). 2023; 13(10):2171-2185.
PMID: 37710078
PMC: 10539267.
DOI: 10.1007/s13555-023-01014-x.
Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases.
Khoshnam-Rad N, Vahedi H, Sadeghi A, Rastegarpanah M, Namazi S, Anushiravani A
Middle East J Dig Dis. 2023; 15(2):83-106.
PMID: 37546508
PMC: 10404092.
DOI: 10.34172/mejdd.2023.327.
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO).
Gyldenlove M, Meteran H, Sorensen J, Fage S, Yao Y, Lindhardsen J
Lancet Reg Health Eur. 2023; 30:100639.
PMID: 37465323
PMC: 10350848.
DOI: 10.1016/j.lanepe.2023.100639.
Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).
Piaserico S, Riedl E, Pavlovsky L, Vender R, Mert C, Tangsirisap N
Front Med (Lausanne). 2023; 10:1185523.
PMID: 37457564
PMC: 10339811.
DOI: 10.3389/fmed.2023.1185523.
Risankizumab: Daily Practice Experience of High Need Patients.
Brunasso A, Burlando M, Amoruso F, Arancio L, Malara G, Manzo R
Biomedicines. 2023; 11(6).
PMID: 37371864
PMC: 10296177.
DOI: 10.3390/biomedicines11061769.
